Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | BMS-986458 |
Synonyms | |
Therapy Description |
BMS-986458 is an E3 ubiquitin ligase-dependent BCL6 degrader, which potentially inhibits tumor growth (Blood (2024) 144 (Supplement 1): 957). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BMS-986458 | BMS 986458|BMS986458 | BCL6 Inhibitor 6 | BMS-986458 is an E3 ubiquitin ligase-dependent BCL6 degrader, which potentially inhibits tumor growth (Blood (2024) 144 (Supplement 1): 957). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06090539 | Phase I | BMS-986458 + Rituximab BMS-986458 | A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas | Recruiting | USA | NLD | FRA | ESP | DEU | CHE | 0 |